08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Prostate-specific transcript 1 (PCGEM1)

Cancer INDICATION: Prostate cancer In vitro studies suggest inhibiting long noncoding RNA (lncRNA) PCGEM1 could help treat castration-resistant prostate cancer (CRPC). PCGEM1 promotes androgen receptor-mediated transcription of metabolic genes in prostate cancer. In prostate cancer...
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Prostate cancer non-coding RNA 1 (PRNCR1); prostate-specific transcript 1 (PCGEM1) In vitro, cell culture and mouse studies suggest inhibiting the long noncoding RNAs...
07:00 , Sep 5, 2013 |  BC Innovations  |  Targets & Mechanisms

lncRNA meets the androgen receptor

Although many long noncoding RNAs are upregulated in cancer, relatively few have been shown to functionally contribute to disease. 1 Now, a U.S. team has found that two lncRNAs act directly on the androgen receptor...
07:00 , Jul 10, 2006 |  BioCentury  |  Strategy

Diagnostic precision

By identifying real markets and focusing on consumer needs, the new generation of diagnostic companies has shaken off the sector's musty high volume, low value image. Using cutting edge technology to develop products that are...